ARGENX SE's ticker is ARGX and the CUSIP is 04016X101. A total of 335 filers reported holding ARGENX SE in Q3 2023. The put-call ratio across all filers is 0.33 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,413,528 | +168.8% | 4,910 | +113.0% | 0.00% | +100.0% |
| Q2 2023 | $897,843 | +10.7% | 2,305 | +5.9% | 0.00% | 0.0% |
| Q1 2023 | $810,833 | -0.6% | 2,176 | +1.1% | 0.00% | 0.0% |
| Q4 2022 | $815,652 | +6.2% | 2,153 | -1.0% | 0.00% | 0.0% |
| Q3 2022 | $768,000 | -55.0% | 2,174 | -51.9% | 0.00% | -50.0% |
| Q2 2022 | $1,706,000 | +244.6% | 4,517 | +187.7% | 0.00% | +300.0% |
| Q1 2022 | $495,000 | +8.1% | 1,570 | +20.3% | 0.00% | 0.0% |
| Q4 2021 | $458,000 | +29.7% | 1,305 | +11.1% | 0.00% | 0.0% |
| Q3 2021 | $353,000 | +11.4% | 1,175 | +11.4% | 0.00% | 0.0% |
| Q2 2021 | $317,000 | -35.2% | 1,055 | -40.5% | 0.00% | 0.0% |
| Q1 2021 | $489,000 | +5.8% | 1,774 | +13.1% | 0.00% | 0.0% |
| Q4 2020 | $462,000 | +10.0% | 1,568 | -1.8% | 0.00% | 0.0% |
| Q3 2020 | $420,000 | +23.9% | 1,597 | +5.8% | 0.00% | 0.0% |
| Q2 2020 | $339,000 | +98.2% | 1,509 | +16.0% | 0.00% | 0.0% |
| Q1 2020 | $171,000 | – | 1,301 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 297,701 | $112,778,070 | 70.21% |
| Artia Global Partners LP | 85,204 | $32,277,831 | 12.30% |
| Avoro Capital Advisors LLC | 1,265,555 | $479,430,201 | 7.16% |
| DCF Advisers, LLC | 25,000 | $9,470,750 | 6.40% |
| Eagle Health Investments LP | 60,300 | $22,843,449 | 5.27% |
| Avidity Partners Management LP | 625,000 | $236,768,750 | 5.13% |
| Bellevue Group AG | 911,100 | $345,152,013 | 4.58% |
| Fairmount Funds Management LLC | 73,526 | $27,853,855 | 4.42% |
| Paradigm Biocapital Advisors LP | 89,556 | $33,926,499 | 3.98% |
| RTW INVESTMENTS, LP | 482,195 | $182,669,932 | 3.73% |